Literature DB >> 21397305

Low-grade serous primary peritoneal carcinoma.

Kathleen M Schmeler1, Charlotte C Sun, Anais Malpica, Michael T Deavers, Diane C Bodurka, David M Gershenson.   

Abstract

OBJECTIVE: 10% of women with serous ovarian cancer have low-grade carcinomas. These patients are diagnosed at a younger age, have a longer overall survival and a lower response rate to platinum-based chemotherapy compared to women with high-grade serous ovarian carcinoma. It remains unclear if these features are similar in women with low-grade primary peritoneal cancer (PPC). To further explore this issue, a retrospective analysis of the clinical and pathologic characteristics of women with low-grade serous PPC was performed.
METHODS: A retrospective study of 53 patients with low-grade serous PPC evaluated at a single institution from 1986 to 2009 was performed. All cases were reviewed by a gynecologic pathologist to confirm low-grade serous PPC.
RESULTS: Median age at diagnosis was 51.7 years (range 27.1-82.4). 46 patients (86.8%) underwent primary surgery, with optimal tumor reduction achieved in 30 patients (65.2%). 48 patients (90.6%) received chemotherapy as part of their initial treatment. At the completion of primary treatment, 66.7% of patients were noted to have persistent or progressive disease. With a median follow-up of 66.1 months, the 5-year PFS was 16%, yet the 5-year OS was 69%.
CONCLUSION: To our knowledge, this is the first report of women with low-grade serous PPC. Similar to low-grade serous ovarian carcinoma, patients with low-grade serous PPC have high rates of persistent disease at the completion of primary treatment yet a long overall survival. Further study focusing specifically on low-grade serous ovarian and primary peritoneal carcinomas is needed to determine the optimal treatment of these diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21397305     DOI: 10.1016/j.ygyno.2011.02.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

Review 1.  When is it safe to omit surgery in primary peritoneal cancer with small volume disease?

Authors:  Rachel Pounds; Sean Kehoe
Journal:  Curr Oncol Rep       Date:  2015-08       Impact factor: 5.075

2.  Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.

Authors:  Heather J Dalton; Nicole D Fleming; Charlotte C Sun; Priya Bhosale; Kathleen M Schmeler; David M Gershenson
Journal:  Gynecol Oncol       Date:  2017-01-27       Impact factor: 5.482

3.  Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.

Authors:  David M Gershenson; Diane C Bodurka; Robert L Coleman; Karen H Lu; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2017-02-21       Impact factor: 44.544

4.  Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.

Authors:  Allison Gockley; Alexander Melamed; Amy J Bregar; Joel T Clemmer; Michael Birrer; John O Schorge; Marcela G Del Carmen; J Alejandro Rauh-Hain
Journal:  Obstet Gynecol       Date:  2017-03       Impact factor: 7.661

5.  Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.

Authors:  David M Gershenson; Diane C Bodurka; Karen H Lu; Lisa C Nathan; Ljiljana Milojevic; Kwong K Wong; Anais Malpica; Charlotte C Sun
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

6.  Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).

Authors:  Lucia Musacchio; Daniela Califano; Michele Bartoletti; Laura Arenare; Domenica Lorusso; Nunzia Simona Losito; Gennaro Cormio; Stefano Greggi; Francesco Raspagliesi; Giorgio Valabrega; Vanda Salutari; Carmela Pisano; Anna Spina; Daniela Russo; Michele Del Sesto; Vincenzo Canzonieri; Francesco Ferraù; Gian Franco Zannoni; Vera Loizzi; Viola Ghizzoni; Claudia Casanova; Valentina Tuninetti; Monika Ducceschi; Vittoria Del Vecchio; Simona Scalone; Domenico Priolo; Francesco Perrone; Giovanni Scambia; Sandro Pignata
Journal:  Br J Cancer       Date:  2022-07-22       Impact factor: 9.075

7.  Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.

Authors:  Kamrunnahar Shanta; Kentaro Nakayama; Mohammad Mahmud Hossain; Sultana Razia; Tomoka Ishibashi; Masako Ishikawa; Hitomi Yamashita; Kosuke Kanno; Seiya Sato; Satoru Nakayama; Yoshiro Otsuki; Satoru Kyo
Journal:  Curr Oncol       Date:  2022-06-01       Impact factor: 3.109

8.  Primary peritoneal serous carcinoma: a clinicopathological and immunohistochemical study of six cases.

Authors:  Teng Hou; Dongxia Liang; Jiehua He; Xu Chen; Yanna Zhang
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

Review 9.  Clinical implications of using molecular diagnostics for ovarian cancers.

Authors:  E C Kohn; S Romano; J-M Lee
Journal:  Ann Oncol       Date:  2013-12       Impact factor: 32.976

10.  Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

Authors:  John Farley; William E Brady; Vinod Vathipadiekal; Heather A Lankes; Robert Coleman; Mark A Morgan; Robert Mannel; S Diane Yamada; David Mutch; William H Rodgers; Michael Birrer; David M Gershenson
Journal:  Lancet Oncol       Date:  2012-12-21       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.